Oncternal Therapeutics (ONCT) Insider Trading & Ownership $1.26 +0.01 (+0.80%) (As of 10/7/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Oncternal Therapeutics (NASDAQ:ONCT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.20%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$92,735.84Number OfInsiders Selling(Last 12 Months)0 Get ONCT Insider Trade Alerts Want to know when executives and insiders are buying or selling Oncternal Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ONCT Insider Buying and Selling by Quarter Ad Stansberry ResearchU.S. Stock Market Now on Verge of Collapse"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He says what's coming next to the U.S. economy could be much worse than anything he's predicted before. And this time, he says, "The trouble is coming straight for Nvidia and the AI market."Click here to see why. Oncternal Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/8/2024Robert James WillsDirectorBuy3,086$8.96$27,650.56 3/28/2024Robert James WillsDirectorBuy6,914$8.48$58,630.72 2/23/2024David F HaleDirectorBuy714$9.04$6,454.56 (Data available from 1/1/2013 forward) ONCT Insider Trading Activity - Frequently Asked Questions Who is on Oncternal Therapeutics's Insider Roster? The list of insiders at Oncternal Therapeutics includes Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent, Robert James Wills, and Salim Yazji. Learn more on insiders at ONCT. What percentage of Oncternal Therapeutics stock is owned by insiders? 11.20% of Oncternal Therapeutics stock is owned by insiders. Learn more on ONCT's insider holdings. Which Oncternal Therapeutics insiders have been buying company stock? The following insiders have purchased ONCT shares in the last 24 months: Chase C Leavitt ($4,350.00), David F Hale ($6,454.56), Gunnar F Kaufmann ($9,830.00), James B Breitmeyer ($29,000.00), Richard G Vincent ($9,000.00), Robert James Wills ($86,281.28), and Salim Yazji ($4,300.00). How much insider buying is happening at Oncternal Therapeutics? Insiders have purchased a total of 20,114 ONCT shares in the last 24 months for a total of $149,215.84 bought. More Insider Trading Tools from MarketBeat Related Companies: CMMB Insider Trades NRXP Insider Trades BCLI Insider Trades UNCY Insider Trades MIRA Insider Trades APRE Insider Trades ATHA Insider Trades KALA Insider Trades CARA Insider Trades TLPH Insider Trades Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: Insiders Are Betting Big on These 2 StocksThis Is the Top Large-Cap Stock Insiders Are BuyingMatador Resources Insiders Keep Buying Its Stock, Should You?Top 3 Small-Cap Stocks Insiders Are Buying Right Now3 Small Cap Stocks That Insiders Are Buying This page (NASDAQ:ONCT) was last updated on 10/7/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredStrikes and Economic Unrest: Are You Prepared for What’s Coming?The rapid advancement of artificial intelligence and automation is reshaping industries and posing threats to ...InvestorPlace | SponsoredNotice: Major payout due November 19th - are you on the list?On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's p...Behind the Markets | SponsoredU.S. Stock Market Now on Verge of Collapse"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He ...Stansberry Research | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.